Exchange & Returns Information
Review Details
(4)
| Generic For | OPDIVO |
|---|---|
| Active Ingredient | NIVOLUMAB |
| Strength | 100MG |
| Manufacturer | BRISTOL MYERS SQUIBB |
| Pack Size | Price Per Unit | Unit Price | QTY | CART | Best Coupon Price MAX DISCOUNT |
|---|---|---|---|---|---|
| 1 BOX - 1 VIAL | $ 315.20 | $ 315.20 |
$ 267.92
Apply ZARVY26 (-15%)
You save $ 47.28
|
||
| 2 BOXES - 2 VIALS | $ 316.00 | $ 632.00 |
$ 537.20
Apply ZARVY26 (-15%)
You save $ 94.80
|
||
| ★ Best Value 3 BOXES - 3 VIALS | $ 314.33 | $ 943.00 |
$ 801.55
Apply ZARVY26 (-15%)
You save $ 141.45
|
Reference information will be available soon.
Opdyta 40mg, solution for injection is a lower-dose formulation of Nivolumab, a PD-1 checkpoint inhibitor designed for precision immunotherapy in cancer treatment. By blocking the PD-1 pathway, Nivolumab restores the immune system’s ability to recognize and destroy tumor cells. This 40mg format offers flexibility in dose titration, especially for pediatric patients or weight-based protocols. It is commonly used in hospitals and oncology centers across various solid tumors and hematologic malignancies, often in combination with agents like Ipilimumab.
- AntiCancer Drugs > Lung Cancer (NSCLC, Mesothelioma) Nivolumab is a foundational immunotherapy for non-small cell lung cancer, often administered alone or in combination with chemotherapy or Ipilimumab. It also plays a key role in managing malignant pleural mesothelioma. > Skin Cancer (Melanoma) Used for unresectable and metastatic melanoma, Nivolumab improves long-term survival outcomes both as a single agent and in combination with CTLA-4 inhibitors. > Kidney Cancer (RCC) Integral to the first-line treatment of advanced renal cell carcinoma. Shows enhanced efficacy when combined with Ipilimumab or tyrosine kinase inhibitors such as Cabozantinib. > Head and Neck Squamous Cell Carcinoma (HNSCC) Used in recurrent or metastatic HNSCC following platinum therapy failure. Offers a survival advantage over standard chemotherapy. > Liver Cancer (HCC) Provides immunologic control in patients with previously treated hepatocellular carcinoma, either alone or with Ipilimumab. > Blood Cancer (Hodgkin Lymphoma) Approved for use in relapsed or refractory classical Hodgkin lymphoma, providing a high durable response rate. > Urothelial and GI Cancers (Gastric, Esophageal, Colorectal) Nivolumab is effective in PD-L1+ or MSI-H/dMMR tumors, both as monotherapy and in combination with Ipilimumab or chemotherapy.
Nivolumab selectively binds to the PD-1 receptor on T cells, blocking its interaction with PD-L1/PD-L2 ligands expressed on tumor cells. This blockade lifts immune suppression, reactivating cytotoxic T-cell activity against tumors. It is a keystone immunotherapy in oncology, particularly in advanced cancers resistant to chemotherapy. The synergy observed with other checkpoint inhibitors like Ipilimumab enhances T-cell priming and expansion, leading to deeper and more sustained responses.
All infusions must be given IV over 30 minutes. Dose and frequency depend on weight, cancer type, and combination strategy. - Melanoma: • Monotherapy: 240 mg q2w or 480 mg q4w • Adjuvant: Up to 1 year post-resection • Combo: Ipi 3 mg/kg + Nivo 1 mg/kg q3w × 4 doses, then Nivo alone - NSCLC: • Monotherapy or Ipi Combo: 240 mg q2w or 480 mg q4w • Chemo Combo: Nivo 360 mg q3w + platinum chemo - RCC: • Mono: 240 mg q2w or 480 mg q4w • Combo: Nivo 3 mg/kg + Ipi 1 mg/kg q3w × 4 doses • With Cabozantinib: Nivo 240 mg q2w + Cabo 40 mg PO daily - Hodgkin Lymphoma, HNSCC, Urothelial Cancer: • 240 mg q2w or 480 mg q4w - Hepatocellular Carcinoma: • Mono: 240 mg q2w or 480 mg q4w • Combo: Nivo 1 mg/kg + Ipi 3 mg/kg q3w × 4 doses - GI Cancers (Esophageal, Gastric, GEJ): • 240 mg q2w or 480 mg q4w (Mono) • Combo: Nivo + fluoropyrimidine/platinum OR Nivo 360 mg q3w + chemo - Colorectal (Adult & Pediatric ≥12 yrs): • <40 kg: 3 mg/kg q2w • ≥40 kg: 240 mg q2w or 480 mg q4w • Combo: Nivo 3 mg/kg + Ipi 1 mg/kg q2w × 4 doses
Store refrigerated at 2°C to 8°C. Protect from light. Do not freeze or shake. Use immediately after dilution or store at 2–8°C for up to 24 hours before administration.
Adverse reactions include immune-mediated colitis, pneumonitis, hepatitis, endocrinopathies (thyroiditis, adrenal insufficiency), and infusion reactions. Fatigue, rash, and nausea are also frequent. Regular monitoring of CBC, liver enzymes, thyroid function, and renal parameters is advised. Severe toxicities may require corticosteroid intervention and discontinuation of therapy.
The injection reached me two days sooner than expected, safely packed.
Package arrived right on time and in perfect condition.
ได้รับสินค้าตรงตามกำหนด ทุกอย่างอยู่ในสภาพดี
The order went through smoothly, no issues.
No combo deals available at the moment.
